Research Confirms Ushio’s Care222® Far UV-C Technology is Effective Against A Variant of SARS-CoV-2
Hiroshima University and Ushio Inc. (Head Office: Tokyo, President and CEO: Koji Naito, hereinafter “Ushio”) have been conducting a joint research project (research title: Study